LVCL.F Stock Overview
Algorae Pharmaceuticals Limited, a biotechnology company, focuses on developing solutions for Parkinson’s disease in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Algorae Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.0041 |
| 52 Week High | AU$0.013 |
| 52 Week Low | AU$0.0037 |
| Beta | 0.74 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -18.00% |
| 3 Year Change | -65.83% |
| 5 Year Change | -86.10% |
| Change since IPO | -95.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| LVCL.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -2.5% | -3.2% |
| 1Y | -18.0% | -3.7% | 19.3% |
Return vs Industry: LVCL.F underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: LVCL.F underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| LVCL.F volatility | |
|---|---|
| LVCL.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LVCL.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine LVCL.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | David Hainsworth | www.algoraepharma.com |
Algorae Pharmaceuticals Limited, a biotechnology company, focuses on developing solutions for Parkinson’s disease in Australia. It is developing NTCELL, an alginate coated capsule to target the treatment of Parkinson’s disease; and AI-116, a novel combination drug candidate, which includes cannabidiol and an off-patent pharmaceutical ingredient treatment for dementia, including Alzheimer’s disease. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023.
Algorae Pharmaceuticals Limited Fundamentals Summary
| LVCL.F fundamental statistics | |
|---|---|
| Market cap | US$10.88m |
| Earnings (TTM) | -US$1.45m |
| Revenue (TTM) | US$27.10k |
401.4x
P/S Ratio-7.5x
P/E RatioIs LVCL.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LVCL.F income statement (TTM) | |
|---|---|
| Revenue | AU$42.02k |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$42.02k |
| Other Expenses | AU$2.29m |
| Earnings | -AU$2.25m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0013 |
| Gross Margin | 100.00% |
| Net Profit Margin | -5,360.41% |
| Debt/Equity Ratio | 0% |
How did LVCL.F perform over the long term?
See historical performance and comparison